Ensitrelvir for the Treatment of Hospitalized Adults With COVID-19: An International Phase 3 Randomized Placebo-controlled Trial
In an international placebo-controlled phase 3 trial of 589 hospitalised adults, adding ensitrelvir to standard care did not significantly improve the day-60 recovery outcome. The result argues against broad inpatient benefit while leaving narrower timing or subgroup questions open.